Harry Clifford

Meet the absolute unit that is Harry Clifford, the guy’s a straight-up beast in the startup and biotech scenes. Dude’s been around the block, and his process is all about pushing the limits of tech and health.

So, Harry’s a proud member of YC’s S17 batch, that’s the real deal, right? That alone shows he’s got the hustle and smarts. But what really sets him apart is his crazy diverse background. He’s worked at some heavy hitters like NVIDIA, yep, the chip giant, and White Scar Ventures, which is all about backing original startups. Plus, he’s got solid experience with Cambridge Cancer Genomics and Cancer Research UK, so he’s deep in the health and biotech game.

He’s also been involved with the University of Cambridge and Nottingham, so academia’s definitely in his DNA. That blend of modern research and startup grind? That’s what makes him tick. Harry isn’t just about tech for tech’s sake, he’s all about using it to beat disease, push healthcare forward, and make a real impact.

From what I gather, Harry’s driven by a serious passion for solving big problems, especially around cancer and health tech. His work at Cambridge Cancer Genomics, for example, is about empowering clinicians with good AI tools, like, giving them superpowers to make faster, better decisions. That’s some advanced stuff. He’s the kind of guy who sees a challenge and jumps into it, not just to tinker but to really change the game.

His story’s also about persistence. Being in YC and having all these experiences means he’s crushed it in different arenas, research, VC, startups. And he’s not just riding the wave; he’s building the wave. His connections with folks like Kevin Hale and projects like Lob show he’s got the vision and the hustle to automate and scale solutions that were once only dreams.

Bottom line? Harry Clifford is a builder, a thinker, a problem-solver. He’s one of those guys who sees the big picture but also gets into the nitty-gritty. Whether it’s biotech research or startup innovation, he’s all about making shit happen. No cap, this guy’s just getting started, and he’s gonna keep disrupting the health tech space for a long time.